VAXX vs. MNPR, GRTX, AEZS, KTRA, ERNA, ABVC, MBRX, AVTX, MTEM, and NCNA
Should you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Monopar Therapeutics (MNPR), Galera Therapeutics (GRTX), Aeterna Zentaris (AEZS), Kintara Therapeutics (KTRA), Eterna Therapeutics (ERNA), ABVC BioPharma (ABVC), Moleculin Biotech (MBRX), Avalo Therapeutics (AVTX), Molecular Templates (MTEM), and NuCana (NCNA). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Vaxxinity currently has a consensus target price of $7.00, suggesting a potential upside of 8,488.96%. Monopar Therapeutics has a consensus target price of $2.00, suggesting a potential upside of 222.58%. Given Vaxxinity's higher probable upside, analysts plainly believe Vaxxinity is more favorable than Monopar Therapeutics.
Monopar Therapeutics has lower revenue, but higher earnings than Vaxxinity. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
83.0% of Vaxxinity shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 41.6% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Monopar Therapeutics had 5 more articles in the media than Vaxxinity. MarketBeat recorded 5 mentions for Monopar Therapeutics and 0 mentions for Vaxxinity. Monopar Therapeutics' average media sentiment score of 0.75 beat Vaxxinity's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.
Vaxxinity has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Monopar Therapeutics' return on equity of -110.42% beat Vaxxinity's return on equity.
Monopar Therapeutics received 34 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 70.91% of users gave Monopar Therapeutics an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Summary
Monopar Therapeutics beats Vaxxinity on 8 of the 15 factors compared between the two stocks.
Get Vaxxinity News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaxxinity Competitors List
Related Companies and Tools
